3/10
05:10 pm
verv
Mutated DNA Restored to Normal in Gene Therapy Advance [The New York Times]
Low
Report
Mutated DNA Restored to Normal in Gene Therapy Advance [The New York Times]
3/4
10:46 am
verv
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at Royal Bank of Canada from $17.00 to $15.00. They now have an "outperform" rating on the stock.
Medium
Report
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at Royal Bank of Canada from $17.00 to $15.00. They now have an "outperform" rating on the stock.
3/3
04:05 pm
verv
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/28
08:13 am
verv
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target raised by analysts at HC Wainwright from $14.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target raised by analysts at HC Wainwright from $14.00 to $15.00. They now have a "buy" rating on the stock.
2/27
07:08 pm
verv
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/27
07:00 am
verv
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
2/21
10:04 pm
verv
Verve Therapeutics, Inc. (NASDAQ: VERV) had its "outperform" rating re-affirmed by analysts at William Blair.
Medium
Report
Verve Therapeutics, Inc. (NASDAQ: VERV) had its "outperform" rating re-affirmed by analysts at William Blair.
2/17
01:34 pm
verv
PCSK9 Inhibitors Market Anticipate to Accelerate in the Coming 10 Years Owing to the Increasing Demand for Innovative Cholesterol-Lowering Drugs | DelveInsight [Yahoo! Finance]
Medium
Report
PCSK9 Inhibitors Market Anticipate to Accelerate in the Coming 10 Years Owing to the Increasing Demand for Innovative Cholesterol-Lowering Drugs | DelveInsight [Yahoo! Finance]
2/3
04:05 pm
verv
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/31
11:11 am
verv
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
1/29
07:00 am
verv
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Medium
Report
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
1/26
10:00 am
verv
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation
Low
Report
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation
1/22
10:00 am
verv
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
High
Report
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
1/19
10:00 am
verv
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation
1/15
10:00 am
verv
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to Connect
Low
Report
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to Connect
1/13
07:00 am
verv
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
Low
Report
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
1/12
10:00 am
verv
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation
1/8
10:00 am
verv
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation
1/8
07:00 am
verv
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
1/5
10:00 am
verv
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Low
Report
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
1/3
04:05 pm
verv
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/2
10:00 am
verv
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect
Low
Report
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect
12/29
10:00 am
verv
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Stockholders to Connect
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Stockholders to Connect
12/26
10:00 am
verv
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
High
Report
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
12/22
10:00 am
verv
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation